多肽介导的核酸药物递送系统研究进展  

A dvances in Peptide-mediated Nucleic Acid Drug Delivery System

作　　者：丁晓然[1] 王升启[1] 

机构地区：[1]军事医学科学院放射与辐射医学研究所,北京100850

出　　处：《药学进展》2015年第2期105-112,共8页Progress in Pharmaceutical Sciences

摘　　要：核酸药物作为新型基因治疗药物备受关注,但生物学稳定性差、易被体内核酸酶降解、生物利用度低、靶组织内聚集浓度低等是制约其发展的主要因素。新的药物递送技术的快速发展在一定程度上解决了核酸药物的稳定性及靶向递送问题,极大地推动了核酸药物的研发进展。尤其是多肽蛋白类递送载体,已成为核酸药物递送系统研究领域的热点之一。介绍核酸药物递送载体多肽修饰的两种主要方式——共价缀合和非共价络合,重点综述近年来多肽缀合物和复合物以及多肽修饰的载体在核酸药物递送系统中的应用研究,探讨多肽介导的核酸药物递送系统在应用中存在的问题,为新型核酸药物递送系统研发提供参考。Nucleic acid drugs （NAs） as new gene therapies have been more concerned. However, the biological instability, susceptibility to nuclease degradation in vivo, low bioavailability and low concentration within the target tissue are the major factors restricting the development of NAs. The rapid development of new drug delivery technologies has solve the problem of NA＇s stability and targeting delivery to a certain extent and greatly promoted the research progress of NAs. Especially, the peptide-based delivery vectors have become one of research hotspots in the field of NA delivery system. The two main ways to modify NA delivery vectors with peptides covalent conjugation and non-covalent complexation were introduced, the applications ofpeptide-based conjugates and complexes and peptide-modified vectors in NA delivery system in recent years reviewed emphatically and the existing issues in the application of peptide-mediated NA delivery system were discussed to provide the reference for research and development of the novel NA delivery system.

关 键 词：多肽载体 核酸药物 药物递送系统 

分 类 号：R943[医药卫生—药剂学]